Teleflex v. Medtronic: Seven Catheter Patents Invalidated for Indefiniteness
Vascular Solutions and the Teleflex group sued Medtronic in Minnesota District Court over seven patents covering guide extension catheter technology, including the GuideLiner and Telescope product lines. After nearly 4.6 years of litigation, the court held every asserted claim invalid — ruling that key claim terms were too indefinite to be construed.
Mass invalidity ruling ends a 4.6-year catheter IP dispute in Minnesota
Filed on 2 July 2019 in the Minnesota District Court, this case pitted the Teleflex group — including Vascular Solutions LLC, Arrow International LLC, Teleflex Life Sciences LLC, Teleflex LLC, and related entities — against Medtronic, Inc. and Medtronic Vascular, Inc. The plaintiffs asserted seven US patents directed at guide extension catheter technology, products sold commercially as the GuideLiner and the Telescope 6F, 7F, and Guide Extension Catheter lines.
On 24 January 2024, the court entered judgment entirely in Medtronic’s favour. The central holding was that the terms ‘substantially rigid portion’ and ‘substantially rigid segment’ — critical to dozens of asserted claims across all seven patents — were incapable of any viable construction, rendering them indefinite under 35 U.S.C. § 112. As a result, claims 8, 9, 13, 17, 18, 23, 24, and 25 of US8,048,032; claims across RE45,380, RE45,776, RE47,379, RE45,760, RE46,116; and claims 4 and 13 of US8,142,413 were all invalidated. Medtronic’s counterclaims for declaratory judgment of invalidity (Counts I–VII) were granted in full, and Teleflex’s infringement claims were dismissed.
The 1,667-day duration reflects the complexity of construing claim language across a six-patent reissue portfolio and one original patent — a multi-front validity battle that is relatively uncommon at the district court level. The outcome turns entirely on claim construction rather than any factual infringement finding, which means the underlying catheter technology itself was never adjudicated. Whether Teleflex will appeal or seek reexamination of surviving claims is not disclosed in the public record.
Filing to settlement in 1667 days
1,667 days — a protracted first-instance dispute by district court standards
How the court reached a complete defense win on indefiniteness
Indefiniteness as a total invalidity weapon
Under 35 U.S.C. § 112, a patent claim is invalid if a person of ordinary skill in the art cannot determine the scope of the claim with reasonable certainty. Here, the court found ‘substantially rigid portion’ and ‘substantially rigid segment’ failed that standard — and because those terms appeared across all asserted claims in all seven patents, the ruling wiped out the entire enforced portfolio in a single stroke.
35 U.S.C. § 112 — indefinitenessNo viable construction found — a high-bar outcome
Courts typically adopt the broadest reasonable interpretation before invalidating on indefiniteness. The court’s finding that ‘no viable construction’ was possible signals that Teleflex could not provide a workable limiting definition, and the intrinsic record offered no reliable anchor. This outcome is relatively rare and suggests the reissue prosecution history may have compounded ambiguity rather than clarified it.
Claim construction failureFive reissue patents amplified rather than reduced exposure
Five of the seven patents are reissue patents (RE45,380; RE45,760; RE45,776; RE46,116; RE47,379). Reissue proceedings are used to correct defects in granted patents, yet here the reissued claims retained the same indefinite terms. This suggests that even multiple rounds of USPTO review did not resolve the ambiguity that ultimately proved fatal in litigation — a cautionary signal for reissue strategy in medical device IP.
Reissue patent vulnerabilityMedtronic’s counterclaims secured affirmative invalidity findings
Medtronic did not merely defend — it pursued declaratory judgment counterclaims (Counts I–VII) that were granted in full. This means invalidity is now adjudicated as a matter of record, not just an unresolved defence. Any future plaintiff asserting these patents faces collateral estoppel issues, and Medtronic has a formal court order it can deploy against any related enforcement attempt.
DJ invalidity — all 7 patentsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Vascular Solutions, LLC | Company | Medical device IP holding group — asserting guide extension catheter patent portfolioSearch in Eureka ↗ |
| Defendant | Medtronic, Inc. | Company | Medtronic, Inc. — global medical device manufacturer, Telescope catheter product lineSearch in Eureka ↗ |
| Plaintiff counsel | Alexander S. Rinn | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | J. Derek Vandenburgh | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | J. Thomas Vitt | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Joseph W. Winkels | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Kenneth E. Levitt | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Megan E. Christner | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Sanjiv P. Laud | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Seung Sub Kim | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Shelleaha L. Jonas | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Tara C. Norgard | Attorney | Counsel for Vascular Solutions, LLCSearch in Eureka ↗ |
| Defendant counsel | Anne E. Rondoni Tavernier | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Barbara Marchevsky | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Cara S. Donels | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Emily Jean Tremblay | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Gregory Hayes Lantier | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Katherine J. Rahlin | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Kurt J. Niederluecke | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Laura L. Myers | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Lora Mitchell Friedemann | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Nirmani Chethana Perera | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Defendant counsel | Sharon E Roberg-Perez | Attorney | Counsel for Medtronic, Inc.Search in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | Minnesota District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The court’s judgment is sweeping in scope: it invalidates specific named claims across all seven asserted patents on a single indefiniteness ground, grants Medtronic’s full slate of DJ counterclaims, and dismisses all of Teleflex’s infringement counts. The phrasing ‘no viable construction is possible’ goes beyond a narrow claim construction ruling — it is an affirmative finding of patent invalidity that binds the parties and creates a strong record for any future challenger. Teleflex retains no surviving infringement position in this action.
US8,048,032 and six related patents — guide extension catheter technology
The asserted portfolio covers guide extension catheter systems — devices used in interventional cardiology to extend the reach of a guiding catheter into coronary anatomy, facilitating balloon, stent, and other device delivery. The core original patent, US8,048,032, relates to catheter designs incorporating a ‘substantially rigid’ proximal segment and a flexible distal portion. The five reissue patents (RE45,380; RE45,760; RE45,776; RE46,116; RE47,379) represent multiple re-prosecution cycles aimed at expanding or clarifying claim coverage. US8,142,413 covers a related catheter construction. The portfolio underpins the commercially successful GuideLiner product.
Guide extension catheters are a high-value niche in the interventional cardiology market, where procedural success often depends on catheter deliverability. A patent portfolio covering this space — if valid — would provide meaningful leverage against competitors including Medtronic’s Telescope line. However, the court’s invalidity ruling on indefiniteness eliminates the entire enforced claim set, leaving competitors free to operate without licence from this portfolio as it was asserted. Remaining Teleflex patent family members not asserted in this case may still carry risk, and practitioners should verify which claims survived the litigation.
Should you run an FTO against the Teleflex guide extension catheter portfolio?
Any company developing, manufacturing, or commercialising guide extension catheters — or adjacent interventional delivery systems — should assess the residual scope of the Teleflex patent family. While all asserted claims in this case have been invalidated, broader family members, continuation applications, and non-asserted patents may still present exposure. The GuideLiner and Telescope product categories are commercially active and likely to attract continued IP attention from multiple parties.
PatSnap Eureka’s FTO Search Agent can map the full Teleflex guide extension catheter patent family — including granted patents, pending continuations, and lapsed applications — against your product’s design parameters. Claim-level monitoring alerts you when new filings in this family publish, so your R&D and legal teams can respond before a product launch. Start with a family tree search on US8,048,032 to anchor the analysis.
Run a freedom-to-operate analysis on USRE045380E to assess your product’s exposure
Run FTO in Eureka →Similar patent cases in interventional cardiology device litigation
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this ruling signals for the vascular catheter IP landscape
A complete portfolio wipeout on indefiniteness is uncommon. This case carries direct lessons for medical device patent drafters, litigators, and competitors.
Relative rigidity language is a litigation liability in catheter patents
Terms like ‘substantially rigid’ are endemic in interventional cardiology device patents. This ruling is a hard signal that courts will not save poorly bounded relative terms through creative construction. Patent teams should audit existing claims for similar language — especially in reissue or continuation filings where the same terms propagate across a large family.
Declaratory judgment counterclaims converted a defence into a lasting record
Medtronic’s decision to pursue DJ counterclaims rather than rely solely on invalidity as a defence created a formal, citable invalidity ruling. Competitors and potential licensees of these patents now have a public court record to rely on. IP teams monitoring enforcement risk around guide extension catheter technology should note this distinction when assessing the Teleflex portfolio’s residual threat.
Vascular v Medtronic — key questions answered
The Minnesota District Court entered judgment for Medtronic on 24 January 2024 after finding all asserted claims across seven Teleflex guide extension catheter patents invalid for indefiniteness. The court ruled ‘substantially rigid portion’ and ‘substantially rigid segment’ were incapable of viable construction, defeating all infringement counts and granting Medtronic’s full declaratory judgment counterclaims.
The court found the claim terms ‘substantially rigid portion’ and ‘substantially rigid segment’ could not be construed because no viable limiting definition was possible based on the patent specifications and prosecution history. Under 35 U.S.C. § 112, claims must define scope with reasonable certainty — a standard these terms failed. The same terms appeared across all seven asserted patents, resulting in portfolio-wide invalidity.
Claims 8, 9, 13, 17, 18, 23, 24, 25 of US8,048,032; claims 8, 9, 14, 19, 27, 43, 44 of RE45,380; claims 25, 27, 29, 30, 32, 36, 37, 49, 52, 54 of RE45,776; claims 33, 34, 44, 46, 51 of RE47,379; claims 25, 28, 29, 32, 44, 48, 53 of RE45,760; claims 4 and 13 of US8,142,413; and claim 46 of RE46,116.
The case centred on guide extension catheter products. Teleflex’s GuideLiner catheter was the primary plaintiff-side product underlying the patent claims. Medtronic’s accused products included the Telescope 6F, Telescope 7F, and the Telescope Guide Extension Catheter — competing interventional cardiology devices in the same functional category.
Medtronic’s seven DJ counterclaims for invalidity were granted in full, meaning invalidity is a court-adjudicated fact, not merely an unresolved defence. This creates a formal public record that may support collateral estoppel arguments in related proceedings and signals to the market that these Teleflex patents carry no enforceable weight in their asserted form.
PatSnap Eureka searches patents and litigation data to answer instantly.